Trending: U.K. Regulator to Launch Expanded Review into Vodafone U.K.'s Joint Venture With Three
1213 GMT - The U.K. Competition and Markets Authority is among the most mentioned topics across news items over the past five hours, according to Factiva data, after the regulator said it would launch a deep review into the planned joint venture between Vodafone U.K. and Three U.K. unless they come up with a solution to its concerns. The regulator said that it believes the deal could result in higher prices for customers and impact investment in U.K. mobile networks. "Whilst Vodafone and Three have made a number of claims about how their deal is good for competition and investment, the CMA has not seen sufficient evidence to date to back these claims," CMA's Julie Bon said. The companies said that the review was an expected step in the process and they looked forward to engaging constructively with the regulator to set out the benefits of the deal. They have five working days to offer a solution otherwise the CMA will refer the deal for a deeper probe. Vodafone shares were up 2.2% at 69.00 pence. Dow Jones & Co. owns Factiva. ( najat.kantouar@wsj.com)
(END) Dow Jones Newswires
March 22, 2024 09:01 ET (13:01 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software